Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.6652W HIGH $5.89
Volume
22.66 K
Value Traded
30.30 K
Short % Float
0.14%
-9.71%Week
-30.78%1 Month
-42.63%3 Month
-16.15%6 Month
-68.15%5 Year
-99.37%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
59.47 M
EPS (TTM)
-0.58
P/E Ratio
-
Ent. Value
3.48 B
Total Shares
19.09 M
Float Shares
18.20 M
Insiders
4.67%
Institutions
2.07%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ATHE Catalyst Timeline
Dated clinical, regulatory and corporate events for Alterity Therapeutics Limited
Catalyst Timeline
Dated clinical, regulatory & corporate events for Alterity Therapeutics Limited
586Total events
6Upcoming
70Tier-1 (high impact)
2007 to 2026Coverage
Upcoming catalysts 2
Event history 50
●Biomarker DataATH434FiledClinical Data
QSM MRI iron signal changes with ATH434 consistent with iron-chaperone mechanism
Multiple System Atrophysource ↗
▲Subgroup AnalysisATH434FiledClinical Data
ATH434 50 mg slowed functional decline ~52% vs placebo at Week 52 after CSF NfL adjustment
Multiple System Atrophysource ↗
▲Poster PresentationATH434FiledPresentation
Poster of ATH434 Phase 2 MSA analyses with CSF NfL covariate presented at 2026 MDS Congress
Multiple System Atrophysource ↗
▲Patent GrantedATH434FiledIP / Competition
USPTO granted new composition of matter patent for ATH434
Multiple System Atrophysource ↗
▲End Of Phase 2 MeetingATH434FiledFDA Meeting
FDA End-of-Phase 2 meeting minutes received confirming registrational pathway
Multiple System Atrophysource ↗
●Quarterly UpdateCorporate
Released Appendix 4C with cash balance of A$37.3 million as at 30 June 2026
▲End Of Phase 2 MeetingATH434FiledFDA Meeting
Successful End-of-Phase 2 meeting with FDA agreeing on key elements of Phase 3 design
Multiple System Atrophysource ↗
◆End Of Phase 2 MeetingATH434FiledFDA Meeting
End-of-Phase 2 meeting with FDA
Multiple System Atrophysource ↗
▲Manufacturing MilestoneATH434FiledCMC / Inspection
First registration batch of ATH434 manufactured for pivotal trial
Multiple System Atrophy (MSA)source ↗
◆Oral PresentationATH434FiledPresentation
ATH434 Clinical Update and Phase 3 Planning at MSA Symposium 2026
Multiple System Atrophy (MSA)source ↗
◆Poster PresentationATH434FiledPresentation
Results from a Randomized, Double-Blind, Placebo-Controlled Study of ATH434 in MSA using CSF NfL as a Covariate at MDSANZ Scientific Meeting
Multiple System Atrophy (MSA)source ↗
◆Oral PresentationPresentation
Quantitative Susceptibility Mapping Detects Progressive Iron Accumulation in Early MSA (Abstract #03335) at ISMRM 2026
Multiple System Atrophy (MSA)source ↗
▲PublicationPresentation
Publication of QSM MRI biomarker study in NeuroImage
Multiple System Atrophysource ↗
▲FDA Feedback ReceivedATH434FiledFDA Meeting
Positive FDA feedback from two Type C meetings
Multiple System Atrophysource ↗
●Oral PresentationATH434FiledPresentation
Three scientific presentations at ISMRM, MDSANZ, and MSA Symposium
Multiple System Atrophy (MSA)source ↗
▲Poster PresentationATH434FiledPresentation
Poster presentation at MDSANZ Scientific Meeting on Phase 2 results using CSF NfL as covariate
Multiple System Atrophysource ↗
▲PublicationATH434FiledPresentation
Peer-reviewed publication in NeuroImage validated QSM of iron as biomarker of MSA
Multiple System Atrophy (MSA)source ↗
◆Oral PresentationATH434FiledPresentation
Virtual KOL event to discuss ATH434 Phase 2 data and Phase 3 planning
Multiple System Atrophysource ↗
▲Type C MeetingATH434FiledFDA Meeting
Second Type C Meeting with FDA on ATH434 Phase 3 program; positive feedback received on CMC elements
Multiple System Atrophysource ↗
▲Oral PresentationATH434FiledPresentation
ATH434 Phase 2 trial data presented at AAN Late Breaking Science Session
Multiple System Atrophysource ↗
◆Oral PresentationATH434FiledPresentation
Late-Breaking Oral Presentation at AAN Annual Meeting: ATH434 Demonstrates Disease-Modifying Signal in MSA Using MuSyCA Composite Scale
Multiple System Atrophysource ↗
▲End Of Phase 2 MeetingATH434FiledFDA Meeting
FDA End-of-Phase 2 meeting confirmed registrational pathway for ATH434 in MSA
Multiple System Atrophy (MSA)source ↗
▲Type C MeetingATH434FiledFDA Meeting
Positive FDA feedback from Type C meeting on CMC elements for Phase 3
Multiple System Atrophy (MSA)source ↗
▲Oral PresentationATH434FiledPresentation
Late-Breaking Science presentation at AAN Annual Meeting showing ATH434 slowed functional decline
Multiple System Atrophy (MSA)source ↗
▲FDA Feedback ReceivedATH434FiledFDA Meeting
Positive FDA feedback from Type C meeting on CMC elements for Phase 3
Multiple System Atrophy (MSA)source ↗
▲FDA Feedback ReceivedATH434FiledFDA Meeting
Positive FDA feedback from Type C Meeting supporting clinical pharmacology and non-clinical development plans for Phase 3 program
Multiple System Atrophy (MSA)source ↗
◆Oral PresentationPresentation
Alterity CEO to participate in Bell Potter Healthcare Horizons Summit fireside chat
▲Type C MeetingATH434FiledFDA Meeting
FDA Type C meeting feedback on clinical pharmacology and non-clinical development
Multiple System Atrophy (MSA)source ↗
▲Topline ReadoutATH434FiledClinical Data
Positive topline data from ATH434-201 Phase 2 trial in MSA
Multiple system atrophysource ↗
◆Management ChangeCorporate
Appointment of new directors (Stamler and Barbaczy) effective immediately after AGM
▲Fast Track DesignationATH434FiledDesignation
FDA Fast Track designation for ATH434 in MSA
Multiple System Atrophysource ↗
▲Orphan Drug DesignationATH434FiledDesignation
Orphan Drug Designation for ATH434 in MSA in US and EU
Multiple system atrophysource ↗
▲Trial CompletionATH434FiledTrial
Completion of two Phase 2 clinical trials for ATH434 in MSA
Multiple System Atrophysource ↗
▲Topline ReadoutATH434FiledClinical Data
Positive topline data from ATH434-201 double-blind study
Multiple system atrophysource ↗
◆Oral PresentationPresentation
Alterity Therapeutics corporate update at Bell Potter Healthcare Conference
▲Oral PresentationATH434FiledPresentation
Oral presentation at AAS 36th International Symposium on the Autonomic Nervous System highlighting impact of ATH434 on orthostatic hypotension and disease progression
Multiple System Atrophysource ↗
●Management ChangeCorporate
Appointment of new Chair, Managing Director, and other leadership roles
Past FDA Catalysts and PDUFA Decisions
How ATHE actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-05-18 | ATH434 | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D21 / 100
Pipeline Score
$0M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.0x
rNPV / MCap
Top 92%
Micro Cap(rank 605 of 658)
Percentile Rank
Alterity Therapeutics Limited faces pipeline headwinds (21/100), with 1 assets in development.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ATH434 Small moleculeNCT05864365 | Multiple System Atrophy | Phase 2 | COMPLETED | 92 | Feb 26, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every ATHE program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ATH434 Fast TrackOrphan | Multiple System Atrophy (MSA) | Phase 2 | 2026-10-09 | clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA; positive data in its open label Phase 2 clinical trial in participants with advanced MSARead More | Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device ConferenceRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Stamler David AllenDirector, Officer (Chief Executive Officer) | Buy | -47,620 | $0.50 | 08/31/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ATHE
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in ATHE for Q2 2026. | ||||
ATHE Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ATHE ranks across every disease it competes in
Competitive Position is a premium feature
See how ATHE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialATHE News
ATHE▲ +1.5%today
Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference
Alterity Therapeutics announced that CEO David Stamler will present at the Canaccord Genuity Drug and Device Conference on October 12, 2026. The presentation will include corporate updates and discussions with investors. The company is focused on developing treatments for neurodegenerative diseases, particularly Multiple System Atrophy (MSA), and is preparing to initiate a Phase 3 pivotal trial.
Read more →ATHE▼ -6.7%on this news
Alterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson’s Disease and Movement Disorders
Alterity Therapeutics presented new analyses from its Phase 2 trial of ATH434 for Multiple System Atrophy (MSA) at the 2026 MDS Congress. The data indicated that ATH434 50 mg significantly slowed functional decline by approximately 52% compared to placebo. The findings support the use of CSF NfL as a covariate for future trials, enhancing the precision of treatment effect measurements.
Read more →ATHEAlterity Therapeutics to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026
Alterity Therapeutics announced that CEO David Stamler will participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026 on September 11. The company is focused on developing therapies for neurodegenerative diseases, particularly Multiple System Atrophy (MSA). Alterity is preparing to initiate a Phase 3 trial for its lead asset, ATH434, which has shown promising results in previous clinical trials.
Read more →ATHEAlterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434
Alterity Therapeutics has received a new U.S. composition of matter patent for ATH434, extending its protection until at least 2045. This patent enhances the strategic value of ATH434 as the company prepares to initiate Phase 3 trials for Multiple System Atrophy (MSA) by the end of 2026. The patent also opens avenues for future development in Parkinson's disease and other neurodegenerative disorders.
Read more →ATHEAlterity Therapeutics to Present at the 46th Annual Canaccord Genuity Growth Conference
Alterity Therapeutics announced that CEO David Stamler will present at the 46th Annual Canaccord Genuity Growth Conference on August 11, 2026. The company is focused on developing disease-modifying therapies for neurodegenerative diseases, particularly Multiple System Atrophy (MSA). They are preparing to initiate a Phase 3 trial for their lead asset, ATH434, which has shown promising results in earlier trials.
Read more →ATHEAlterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update
Alterity Therapeutics reported a positive End-of-Phase 2 meeting with the FDA, confirming a registrational pathway for its drug ATH434 in treating Multiple System Atrophy (MSA). The company plans to initiate a pivotal Phase 3 trial by the end of 2026, with a focus on maximizing shareholder value through strategic funding. Additionally, a recent cash flow report shows a healthy cash balance and a significant R&D tax incentive refund.
Read more →ATHE▲ +5.1%on this news
Alterity Therapeutics to Participate in the Virtual BTIG Biotechnology Conference 2026
Alterity Therapeutics will participate in the BTIG Biotechnology Conference 2026, with CEO David Stamler hosting one-on-one meetings with investors. The company is focused on developing therapies for neurodegenerative diseases, particularly Multiple System Atrophy (MSA). They are preparing to initiate a pivotal Phase 3 trial following positive Phase 2 trial results.
Read more →ATHE▼ -6.8%on this news
Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy
Alterity Therapeutics has received official FDA minutes confirming the outcomes of its End-of-Phase 2 meeting for ATH434 in treating Multiple System Atrophy (MSA). The FDA agreed that a single pivotal Phase 3 trial, along with confirmatory evidence, could support approval. The company plans to initiate Phase 3 trial activities by the end of 2026.
Read more →ATHE▲ +9.4%on this news
Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy
Alterity Therapeutics announced a successful End-of-Phase 2 meeting with the FDA, achieving alignment on the Phase 3 program for ATH434 in Multiple System Atrophy (MSA). The FDA approved key elements including the study population, dosing regimen, and primary endpoint. The pivotal trial is set to begin by the end of 2026, following promising Phase 2 results.
Read more →ATHEAlterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy
Alterity Therapeutics announced advancements in its development program for ATH434, aimed at treating Multiple System Atrophy (MSA). Presentations at medical conferences highlighted promising Phase 2 data, including significant slowing of disease progression. The company plans to hold an end-of-Phase 2 FDA meeting in mid-2026 to discuss the path forward for Phase 3 trials.
Read more →ATHEAlterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy
Alterity Therapeutics announced a peer-reviewed study demonstrating that quantitative susceptibility mapping (QSM) MRI effectively detects disease-specific iron accumulation in Multiple System Atrophy (MSA) patients. This method can differentiate MSA from Parkinson's disease and correlates with clinical severity, supporting the use of QSM as an objective imaging biomarker. The findings enhance the potential for earlier diagnosis and monitoring of therapies like Alterity's ATH434.
Read more →ATHEAlterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026
Alterity Therapeutics has announced its participation in several medical conferences in May 2026, where it will present findings related to its development program for Multiple System Atrophy (MSA). Key presentations will include updates on the clinical efficacy of its lead asset, ATH434, and its Phase 3 trial plans. The conferences will take place in locations such as Cape Town, Sydney, and London.
Read more →ATHEAlterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update
Alterity Therapeutics has reported positive developments regarding its ATH434 program for Multiple System Atrophy (MSA). The company has received FDA alignment for its Phase 3 program and presented new efficacy data from its Phase 2 trial. Leadership has been strengthened with new appointments, and discussions for strategic collaborations are ongoing. The company maintains a solid cash position.
Read more →ATHEAlterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy
Alterity Therapeutics has received positive feedback from the FDA following its second Type C Meeting regarding the Phase 3 program for ATH434 in treating Multiple System Atrophy (MSA). This feedback supports the company's plans for chemistry, manufacturing, and control elements of the program. The company is preparing for a pivotal trial and aims to finalize plans with the FDA by mid-2026.
Read more →ATHE▼ -6.5%on this newsshared move
Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology
Alterity Therapeutics presented new analyses of ATH434’s Phase 2 trial data during a Late Breaking Science Session at the American Academy of Neurology meeting. The results demonstrated a significant reduction in functional decline in Multiple System Atrophy (MSA) patients using the MuSyCA composite scale. The data confirmed ATH434’s efficacy in slowing disease progression, reinforcing the drug's clinical profile and paving the way for Phase 3 trial preparations.
Read more →ATHE▲ +12.6%on this news· ran to +30% by day 1shared move
Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors
Alterity Therapeutics has appointed Ann Cunningham as an independent Non-Executive Director. With over 25 years in the biotech sector, Cunningham's expertise is expected to enhance the company's strategic direction as it prepares for the Phase 3 development of ATH434 for Multiple System Atrophy. Her experience in commercial strategy will be crucial for the company's growth.
Read more →ATHE▲ +6.4%on this news· ran to +30% by day 3shared move
Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual Meeting
Alterity Therapeutics announced that Dr. Daniel Claassen will present at the AAN Annual Meeting. The presentation will focus on the company's lead asset, ATH434, which has shown promising results in treating Multiple System Atrophy (MSA). Alterity is preparing to initiate a Phase 3 trial for this rare disease, furthering its commitment to neurodegenerative disease therapies.
Read more →ATHEAlterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System Atrophy
Alterity Therapeutics announced a virtual KOL event to discuss ATH434, its lead candidate for treating Multiple System Atrophy (MSA). The event will feature insights from prominent experts in the field, including Dr. Roy Freeman and Dr. Daniel Claassen. It aims to address the unmet needs in MSA treatment and provide updates on ongoing clinical trials.
Read more →ATHE▲ +13%on this news
Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program
Alterity Therapeutics has announced that it received positive feedback from the FDA following a Type C Meeting regarding its Phase 3 program for ATH434, aimed at treating Multiple System Atrophy (MSA). This feedback confirms alignment with the FDA on critical clinical and non-clinical aspects as the company prepares to initiate the pivotal trial. CEO David Stamler highlighted this as a significant step toward further discussions, including an upcoming End-of-Phase 2 meeting scheduled for mid-2026.
Read more →About Alterity Therapeutics Limited
HeadquartersMelbourne
Founded1997
BIOPHARMAWATCH ELITE PLUS
Trade the next ATHE catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime